5MP2 Stock Chart & Stats
€56.50
--
Market closed
€56.50
--
Day’s Range― - ―
52-Week Range€56.50 - €56.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€655.06K
Enterprise Value-€6.77M
Total Cash (Recent Filing)€8.52M
Total Debt (Recent Filing)€60.89K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Sep 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-536.25
Shares Outstanding828,923
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€6.72K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetVery low debt and a meaningful increase in equity and total assets provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D spending, and preserves optionality to fund trials or partnerships without immediate severe liquidity pressure.
Improving Operating Cash BurnA materially smaller operating cash outflow year-over-year signals better cost control or program prioritization. This trend extends runway relative to prior periods, lowers immediate financing needs, and increases the chance management can advance key trials to value-driving milestones before raising large new capital.
Focused Clinical-stage R&D Business ModelA concentrated focus on oncology and serious diseases with a lean team aligns resources on high-value clinical development. For a small biotech, a clear R&D focus increases the probability that successes in trials materially re-rate the company, while limited commercial overhead preserves capital for development milestones.
Bears Say
No Revenue / Persistent LossesZero revenue and ongoing operating and net losses reflect a pre-commercial lifecycle that depends entirely on successful clinical outcomes and external financing. Over the medium term, this increases execution risk: trial failures or delays can erode capital and value, while continued losses pressure shareholder returns and strategic options.
Negative Free Cash Flow And Funding DependencySustained negative free cash flow requires external capital to maintain operations and advance trials. Even with improved burn, the company remains dependent on financings, which risks dilution, execution delays if markets tighten, and management distraction from R&D to capital raises—structural vulnerabilities for biotechs.
Governance And Dilution Risk From Capital ActionsA sweeping capital reorganization and board authority to issue equity materially increases the company's ability to raise dilutive capital and alter share structure. Coupled with recent financings and shareholder pushback, this raises medium-term governance uncertainty and the risk of dilution that can affect long-term investor alignment.
Biodexa Pharmaceuticals News
5MP2 FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was €56.50 and its highest was €56.50 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is €655.06K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2026 which is in 46 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Mar 27, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is 0.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 828,923 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:5MP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―